We have located links that may give you full text access.
Controlled Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't
Topical antibiotic treatment reduces tympanostomy tube biofilm formation.
Laryngoscope 2011 May
OBJECTIVES: Single doses of different ototopical antibiotic preparations (OAPs) have been shown to have an unequal reduction of post tympanostomy tube otorrhea (PTTO). Microbial biofilm formation on the tympanostomy tube (TT) has been implicated as one cause of PTTO. The goal of this study was to determine if TT exposure to a single dose of OAP reduces biofilm formation by Pseudomonas aeruginosa.
STUDY DESIGN: Prospective and controlled.
METHODS: Fluoroplastic TTs were briefly exposed to plasma, followed by one of three OAPs (ofloxacin, neomycin/polymyxin B/hydrocortisone, or ciprofloxacin/dexamethasone) or saline (20 TT per group). TTs were placed in growth media with P. aeruginosa and incubated for 4 days, during which total bacterial growth was monitored by media turbidity. At 4 days, planktonic organisms were killed and biofilm development was measured with microbial counts.
RESULTS: Bacterial growth was significantly delayed by OAPs, with the least growth seen with ciprofloxacin/dexamethasone followed by ofloxacin and neomycin/polymyxin B/hydrocortisone (P ≤ .0001). At day 4, bacterial growth was less with ciprofloxacin/dexamethasone than ofloxacin and neomycin/polymyxin B/hydrocortisone (P < .05). After 4 days, biofilm counts were lower on OAP-treated than saline-treated TTs (P = .0015) with both ciprofloxacin/dexamethasone and ofloxacin significantly less than saline (P < .05). Biofilm counts were not significantly different between OAPs (P > .05).
CONCLUSIONS: Treatment of TTs with ototopical antibiotic preparations reduces P. aeruginosa growth and biofilm formation in vitro. This may, in part, explain the reduction of PTTO rates observed with single doses of OAPs.
STUDY DESIGN: Prospective and controlled.
METHODS: Fluoroplastic TTs were briefly exposed to plasma, followed by one of three OAPs (ofloxacin, neomycin/polymyxin B/hydrocortisone, or ciprofloxacin/dexamethasone) or saline (20 TT per group). TTs were placed in growth media with P. aeruginosa and incubated for 4 days, during which total bacterial growth was monitored by media turbidity. At 4 days, planktonic organisms were killed and biofilm development was measured with microbial counts.
RESULTS: Bacterial growth was significantly delayed by OAPs, with the least growth seen with ciprofloxacin/dexamethasone followed by ofloxacin and neomycin/polymyxin B/hydrocortisone (P ≤ .0001). At day 4, bacterial growth was less with ciprofloxacin/dexamethasone than ofloxacin and neomycin/polymyxin B/hydrocortisone (P < .05). After 4 days, biofilm counts were lower on OAP-treated than saline-treated TTs (P = .0015) with both ciprofloxacin/dexamethasone and ofloxacin significantly less than saline (P < .05). Biofilm counts were not significantly different between OAPs (P > .05).
CONCLUSIONS: Treatment of TTs with ototopical antibiotic preparations reduces P. aeruginosa growth and biofilm formation in vitro. This may, in part, explain the reduction of PTTO rates observed with single doses of OAPs.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association.Circulation 2024 April 19
Essential thrombocythaemia: A contemporary approach with new drugs on the horizon.British Journal of Haematology 2024 April 9
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app